KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Xenon Pharmaceuticals (XENE) over the last 9 years, with Q3 2025 value amounting to $7.1 million.

  • Xenon Pharmaceuticals' Other Non-Current Assets fell 477.85% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 477.85%. This contributed to the annual value of $7.5 million for FY2024, which is 135.21% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $7.1 million for Q3 2025, which was down 477.85% from $9.2 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $9.2 million during Q2 2025, with a 5-year trough of $7.1 million in Q3 2025.
  • For the 4-year period, Xenon Pharmaceuticals' Other Non-Current Assets averaged around $7.7 million, with its median value being $7.5 million (2024).
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first tumbled by 820.45% in 2024, then soared by 2389.43% in 2025.
  • Quarter analysis of 4 years shows Xenon Pharmaceuticals' Other Non-Current Assets stood at $7.8 million in 2022, then decreased by 4.58% to $7.4 million in 2023, then increased by 1.35% to $7.5 million in 2024, then fell by 5.1% to $7.1 million in 2025.
  • Its Other Non-Current Assets was $7.1 million in Q3 2025, compared to $9.2 million in Q2 2025 and $8.1 million in Q1 2025.